NEW
YORK, Sept. 24, 2024 /PRNewswire/ -- Report with
market evolution powered by AI - The Global Vaccine Research
Market size is estimated to grow by USD 21.4 billion from 2024-2028, according to
Technavio. The market is estimated to grow at a CAGR of
10.84% during the forecast period. High
prevalence of infectious diseases is driving market
growth, with a trend towards adoption of AI to speed up R
and D of vaccines, However, high cost of vaccine
research, development, and manufacturing poses a challenge -
Key market players include Abbott Laboratories, Astellas Pharma
Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd.,
CanSino Biologics Inc., Creative Biogene, CSL Ltd., Daiichi Sankyo
Co. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Johnson
and Johnson Services Inc., Merck and Co. Inc., Moderna Inc.,
Novavax Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi SA, Serum
Institute of India Pvt. Ltd., and Takeda Pharmaceutical Co.
Ltd..
AI-Powered Market Evolution Insights. Our comprehensive market
report ready with the latest trends, growth opportunities, and
strategic analysis- View your snapshot now
Forecast
period
|
2024-2028
|
Base Year
|
2023
|
Historic
Data
|
2018 - 2022
|
Segment
Covered
|
End-user (Public and
Private), Age Group (Pediatric and Adult), and Geography (North
America, Europe, Asia, and Rest of World (ROW))
|
Region
Covered
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Key companies
profiled
|
Abbott Laboratories,
Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat
Biotech Ltd., CanSino Biologics Inc., Creative Biogene, CSL Ltd.,
Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc.,
GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck and
Co. Inc., Moderna Inc., Novavax Inc., Panacea Biotec Ltd., Pfizer
Inc., Sanofi SA, Serum Institute of India Pvt. Ltd., and Takeda
Pharmaceutical Co. Ltd.
|
Key Market Trends Fueling Growth
Artificial Intelligence (AI) is revolutionizing the vaccine
research market by transforming the way new vaccines are discovered
and developed. AI technologies help convert vast amounts of data
into valuable insights, enabling a deeper understanding of the
diseases to be treated. This knowledge aids in designing more
effective clinical trials and accelerating the vaccine development
process. For instance, AstraZeneca Plc utilizes AI across its
Research and Development (R&D) activities to analyze diverse
data and information, enhancing disease understanding and
identifying promising drug targets. Additionally, AI tools are
employed for real-time image analysis, assisting researchers in
discovering new genetic mutations and variations in viruses. This
aids in identifying new virus strains, thereby driving the growth
of the vaccine research market. AI's potential to increase R&D
productivity and efficiency makes it a significant trend in the
vaccine research industry.
The vaccine research market is experiencing significant growth
due to the increasing demand for immunization programs against
various diseases. Clinical trials are ongoing for therapeutic
vaccines to combat conditions like cancer, allergies, and
physiological disorders. Pregnant individuals are a focus area,
with research in gestational age vaccines. Vaccines are being
developed for infectious diseases such as meningitis and pneumonia,
as well as chronic conditions like hypertension and dyslipidemia.
Self-antigens and adjuvants are key components in vaccine
development. Animal studies and collaborations between vaccine
manufacturers, genomic research centers, academic institutions,
private laboratories, diagnostic companies, and hospital settings
are driving innovation. Vaccines for diseases like diphtheria,
tetanus, HPV, MMR, rotavirus, influenza, hepatitis B, chickenpox,
polio, BCG, yellow fever, and more are in production. Government
immunization programs and preventive healthcare initiatives are
also boosting the market.
Insights on how AI is driving innovation, efficiency, and market
growth- Request Sample!
Market Challenges
- The development of vaccines is crucial in combating various
infectious and life-threatening diseases. However, the high costs
associated with research, development, and manufacturing have a
significant impact on the global vaccine market. According to a
study by the Coalition for Epidemic Preparedness Innovations
(CEPI), the cost of developing a single epidemic-causing infectious
disease vaccine, from pre-clinical trials to Phase IIa, ranges from
USD31-USD68
million, with an average of USD84-USD112
million to advance at least one vaccine to the end of Phase
IIa trials. Vaccine manufacturing facilities also incur substantial
fixed and ongoing maintenance costs, estimated to be approximately
USD50-500 million per antigen. These
high costs contribute to the expensive nature of vaccines, which
can negatively impact patient compliance and adherence to vaccine
protocols, limiting market growth. To mitigate this challenge,
there is a need to develop vaccines with novel routes of
administration and lower costs. The high cost of vaccine research,
development, and manufacturing will continue to impact the growth
of the global vaccine research market during the forecast
period.
- The vaccine market faces several challenges in developing
effective vaccines for various diseases such as Mumps and
Varicella, Hepatitis, Influenza, Typhoid, Meningococcal, Rabies,
Japanese Encephalitis, and Yellow Fever. Vaccines come in different
forms including Injectable, Oral, and Nasal. These vaccines work by
stimulating the immune system to provide active acquired immunity
against specific microorganisms or toxins. Major diseases like
Tetanus, Pertussis, Measles, and Polio have seen successful
vaccination efforts. However, ongoing research is required for
Pediatric vaccines like Rotavirus and Human Papillomavirus (HPV),
which prevent Cervical cancer. Private organizations play a crucial
role in vaccine research, with next-generation vaccines like mRNA
vaccines showing promise. Distribution channels include Community
Hospitals, Hospitals, Specialty Centers, Clinics, Hospital
Pharmacy, Retail Pharmacy, and Online Pharmacy. Challenges include
maintaining the cold chain for certain vaccines and ensuring timely
and equitable access to vaccines. Vaccines protect against
Pathogens, reducing Morbidity and Mortality. DPT, Hepatitis,
Influenza, Typhoid, Meningococcal, Rabies, Japanese Encephalitis,
and Yellow Fever vaccines are essential for Public health. Vaccines
for diseases like HPV and Rotavirus are critical for preventing
long-term health issues. In summary, the vaccine market faces
challenges in developing effective vaccines for various diseases,
ensuring equitable distribution, and maintaining the cold chain.
Ongoing research and collaboration between public and private
sectors are crucial for addressing these challenges and improving
global health.
Insights into how AI is reshaping industries and driving
growth- Download a Sample Report
Segment Overview
This vaccine research market report extensively covers market
segmentation by
- End-user
- Age Group
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Public- The global vaccine research
market's public segment is experiencing significant growth due to
substantial investments by government organizations in the research
and development (R&D) of vaccines. Notable examples include the
US National Institute of Allergy and Infectious Diseases (NIAID)
and the National Institutes of Health (NIH). In response to the
COVID-19 pandemic, governments worldwide have made substantial
investments, with the US alone spending approximately USD31.2 billion in 2020 and an additional
USD31.9 billion in 2023 on COVID-19
vaccine development. India's
Department of Biotechnology (DBT) also plays a crucial role, with
initiatives like the Indo-US Vaccine Action Program (VAP), Mission
COVID Suraksha, Ind-CEPI Mission, and the National Biopharma
Mission (NBM) aimed at strengthening vaccine R&D. These
programs have led to significant achievements, such as the low-cost
Rotavirus vaccine and progress towards vaccines for diseases like
dengue, malaria, COVID-19, and tuberculosis. The public segment's
growth is expected to continue throughout the forecast period.
Download complimentary Sample Report to gain insights
into AI's impact on market dynamics, emerging trends, and future
opportunities- including forecast (2024-2028) and historic data
(2018 - 2022)
Research Analysis
The vaccine research market encompasses the development,
testing, and production of various types of vaccines to prevent or
treat a range of diseases. Immunization programs around the world
rely on ongoing research to create new vaccines and improve
existing ones. Clinical trials play a crucial role in vaccine
development, ensuring safety and efficacy before they are brought
to market. Vaccines are being researched for various conditions,
including cancer, allergies, and physiological disorders. Pregnant
individuals and their developing fetuses are also a focus, with
vaccines in development for gestational age and therapeutic
purposes. Several types of vaccines are under investigation,
including subunit, recombinant, polysaccharide, conjugate,
live-attenuated, inactivated, and toxoid vaccines. Some examples of
vaccines in development include pneumococcal vaccines, diphtheria,
tetanus, HPV, MMR, rotavirus, influenza, hepatitis B, chickenpox,
polio, and combination vaccines. These vaccines employ different
technologies and target various diseases, expanding the scope of
preventative healthcare.
Market Research Overview
The vaccine research market encompasses the development,
testing, and production of vaccines for various health conditions.
Immunization programs worldwide utilize clinical trials to evaluate
the safety and efficacy of new vaccines. Vaccine development
targets infectious diseases such as meningitis, pneumonia, and
polio, as well as physiological disorders like hypertension,
dyslipidemia, Alzheimer's, and inflammatory diseases. Therapeutic
vaccines are under investigation for cancer and allergies. Vaccines
are produced using antigens, adjuvants, self-antigens, and various
technologies like conjugate, recombinant, toxoid, and
live-attenuated vaccines. Animal studies are crucial in vaccine
research. Vaccines are administered through injectable, oral, and
nasal methods in community hospitals, hospitals, specialty centers,
clinics, hospital pharmacies, retail pharmacies, and online
pharmacies. Vaccines are available as combination vaccines,
monovaccines, subunit, recombinant, polysaccharide, live-attenuated
vaccines, inactivated vaccines, and DNA vaccines. Routine,
recommended, required, pediatric, and adult vaccines are essential
for preventive healthcare against diseases like measles, mumps,
varicella, diphtheria, tetanus, hepatitis, influenza, typhoid,
meningococcal, rabies, Japanese encephalitis, and yellow fever.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- End-user
-
- Age Group
-
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/the-vaccine-research-market-is-projected-to-grow-by-usd-21-4-billion-from-2024-2028--with-ai-redefining-the-landscape-and-rising-infectious-diseases-driving-revenue---technavio-302255237.html
SOURCE Technavio